Low-Molecular-Weight Heparins: A New Therapeutic Approach to Thrombosis Proceedings
J. Monasterio, Meyer M. Samama
Karger, 1996 - Medical - 65 pages
Low-molecular-weight (LMW) heparins are increasingly used in the prevention and treatment of thromboembolic disease because, compared to unfractionated heparins, they show a higher benefit/risk ratio and better clinical convenience. This special issue reports the proceedings of a symposium which reviewed all the available data on the properties of these agents and their therapeutic applications. Several contributions present studies on the use of LMW heparins in the prophylaxis of venous thromboembolism after surgery and in nonsurgical situations, as well as in the treatment of established venous thrombosis. Arterial thrombosis as another potential indication for LMW heparins is discussed. Authoritative and up-to-date, this publication is essential reading for anyone dealing with thromboembolic disease from a pharmacological or a clinical point of view.
What people are saying - Write a review
We haven't found any reviews in the usual places.
ACLM Amax anti anti-factor IIa activity anti-IIa anticoagulant antithrombin III antithrombotic arterial bioavailability bleeding bypass Ca-heparin coagulation compared controlled trials dalteparin deep venous thrombosis deep-vein thrombosis disease dosage dose drug efficacy and safety enoxa enoxaparin enoxaparin group factor Xa Fragmin Frydman GAGs Haemostasis half-life hepa heparin group heparin prophylaxis Hirsh I*fibrinogen incidence of DVT inhibition intravenous IU anti-Xa Karger lecular LMW heparins LMWHs low mo low molecular weight low-molecular-weight heparins medical patients ment mg enoxaparin ml/min molecular weight heparin myocardial infarction nadroparin parin parnaparin patients undergoing pharmacokinetic pharmacological placebo plasma anti-Xa activity platelet postoperative Prof prophylaxis pulmonary embolism randomised randomized ratio renal risk factors risk of thrombosis Samama standard heparin subcutaneous surgery Table therapeutic therapy Thromb Haemost Thromb Res thrombin thromboembolic events thromboembolic risk tients tinzaparin tion total body clearance treatment of deep unfractionated heparin vascular vein thrombosis venous thromboembolism vention